Our Team Of ADC & Antibody Engineering Experts

Doug Chapnick, PhD
Dr. Doug Chapnick is a veteran of cell biology with 20 years’ experience engineering in the life sciences space. He led technology development and research in the DARPA funded ‘Rapid Threat Assessment (RTA)’ project at the University of Colorado, Boulder. He founded BioLoomics to apply principles from the RTA project to overcome market-wide throughput limitations for activity-based discovery of antibodies. Doug received his PhD in Biochemistry from University of Colorado, Boulder, and has authored over 17 academic research publications ranging in focus from cell biology to drug mechanisms of action.

Kurt Gish, PhD
Dr. Kurt Gish has more than 25 years of experience in antibody-drug conjugates for oncology, starting with scientist positions at Affymetrix and Eos Biotechnology, followed by positions as Director of Biologics Technologies at PDL BioPharma, and Research Fellow at AbbVie. With his expertise in target discovery and therapeutics development, he has led two ADC products from concept into phase I human trials and is the inventor on 27 issued US patents. He earned his Ph.D. in Biology at Stanford University, followed by a post-doctoral fellowship in molecular immunology at the DNAX Research Institute (now Merck Research Laboratories). Kurt also serves on the Scientific Advisory Board of the Myeloma Investment Fund of the Multiple Myeloma Research Foundation.

Michael Holden, PhD
Dr Michael Holden is a PhD-trained chemist with deep specialization in protein science and antibody drug discovery. With six years of experience in pharmaceutical development, he has contributed to multiple Investigational New Drug (IND) and Biologics License Application (BLA) filings, bringing a strong foundation in organic chemistry, bioconjugation strategies, and complex biologics. At Regeneron, he founded and led a core research group, driving innovation in antibody-based therapeutics and overseeing the generation, characterization, and deployment of more than 1,000 proteins. His expertise spans protein engineering, antibody characterization, and developability assessments, with a strong focus on CMC strategies to ensure the manufacturability and stability of biologics. Passionate about advancing novel therapeutics, he also experiments with open-source models and code in his free time, exploring computational tools to accelerate drug discovery.

Nicole Beach
Nicole has over 20 years of experience as an Office Manager and Human Resources professional with experience in event planning, team building, and employee workplace management and deep experience in startups. With a Masters degree in Organizational Leadership specializing in HR Management, she is highly organized, extremely personable and professional.

Zachary Dobson, PhD
Biochemistry PhD in structural biology, specializing in protein engineering. With experience as a protein scientist in drug discovery, I am passionate about understanding and manipulating protein structures to innovate therapeutics. Dedicated to scientific excellence, I aim to contribute to the development of transformative solutions in healthcare. Outside of the lab you can find me in the mountains chasing Colorado cutthroats.

Mike Minson, PhD
Mike is an experienced research biochemist coming from ArcherDX and Sartorius with expertise in developing high throughput assays for cell screening using a variety of techniques including NGS, microscopy, and flow cytometry. During his postdoctoral and graduate work at the University of Colorado Boulder, he studied the immune response to bacterial infection using FRET biosensors in primary macrophages. Mike is focused on bringing the drug discovery and downstream analysis of candidates to scale.

Clara Ross, MS
Clara is a protein scientist coming from Watchmaker Genomics with 4+ years of experience in protein purification ranging from small scale prototyping to large scale manufacturing. She has additional experience in protein expression, characterization and DNA/RNA library preparation. Prior to her work in industry, Clara obtained her master’s degree from New Mexico State University where she studied Rho Family GTPases during oocyte meiosis using fluorescent biosensors and 3D live-cell microscopy.

Claire Armstrong, PhD
Claire has over 10 years of experience as a research scientist, specializing in high-throughput assay development, cellular signaling, and single-cell fluorescence microscopy. During her PhD and postdoctoral work at the University of Colorado, she studied the molecular mechanisms driving cell-cycle commitment using single-cell timelapse microscopy of fluorescent biosensors. Claire specializes in driving forward the selection and validation of therapeutic antibody scaffolds via cell-based assay development, single-cell screening, and cell picking microscopy.

Rachel Langston, PhD
Rachel is an experienced molecular biologist coming from Inscripta with expertise in DNA repair and genetics. She is skilled at developing protocols for large-scale mutagenesis. During her postdoctoral work at the IBPC she developed a novel CRISPR-based protocol to study DNA replication and telomere regulation. At BioLoomics, Rachel is focused on optimizing and scaling library production to more efficiently identify drug candidates.

Keiran McGee
Keiran is a graduate of the University of Colorado Boulder where he earned a Bachelor of Arts in Biochemistry. There, he gained lab-based research experience while working on the optimization of an RNA purification method for application in a novel biosensor production pipeline. He is excited to support the work of BioLoomics, while also being able to continue his involvement in research here on Colorado’s Front Range. Outside of the lab, Keiran doubles as a musician, playing bass in the CU Campus Orchestra and singing in the Rocky Mountain Chorale.

Kaitlyn Shafer
Kaitlyn holds a BS in Biochemistry from the University of Denver. She has experience implementing and creating quality control standards and protocols in the diagnostic industry. At BioLoomics, she supports our DNA and cell biology scientists with a wide range of daily tasks including solution preparation, experimental support at different stages, and inventory management. She's focused on developing industry skills in preparation for pursuing a graduate degree.

Ted Kee
Ted has over 12 years of biotech industry experience, specializing in Manufacturing Science and Technology (MSAT). He has held process development and engineering positions at several industry-leading pharmaceutical companies. Ted relocated to Colorado from California in 2019 to co-found BioLoomics and lead the effort to streamline, standardize, and scale up BioLoomics’ laboratory operations.

Jeremy Jacobsen, MS
Jeremy operates at the intersection of mechanical and electrical engineering and data analysis with an emphasis on biological data sets. Prior to joining BioLoomics, he was an analyst for the DARPA Rapid Threat Assessment project at the University of Colorado, Boulder. He specializes in large multidimensional datasets and has applied this expertise to proteomics, metabolomics, and microscopy data.

Doug Chapnick, PhD
Dr. Doug Chapnick is a veteran of cell biology with 20 years’ experience engineering in the life sciences space. He led technology development and research in the DARPA funded ‘Rapid Threat Assessment (RTA)’ project at the University of Colorado, Boulder. He founded BioLoomics to apply principles from the RTA project to overcome market-wide throughput limitations for activity-based discovery of antibodies. Doug received his PhD in Biochemistry from University of Colorado, Boulder, and has authored over 17 academic research publications ranging in focus from cell biology to drug mechanisms of action.

Kurt Gish, PhD
Dr. Kurt Gish has more than 25 years of experience in antibody-drug conjugates for oncology, starting with scientist positions at Affymetrix and Eos Biotechnology, followed by positions as Director of Biologics Technologies at PDL BioPharma, and Research Fellow at AbbVie. With his expertise in target discovery and therapeutics development, he has led two ADC products from concept into phase I human trials and is the inventor on 27 issued US patents. He earned his Ph.D. in Biology at Stanford University, followed by a post-doctoral fellowship in molecular immunology at the DNAX Research Institute (now Merck Research Laboratories). Kurt also serves on the Scientific Advisory Board of the Myeloma Investment Fund of the Multiple Myeloma Research Foundation.

Michael Holden, PhD
Dr Michael Holden is a PhD-trained chemist with deep specialization in protein science and antibody drug discovery. With six years of experience in pharmaceutical development, he has contributed to multiple Investigational New Drug (IND) and Biologics License Application (BLA) filings, bringing a strong foundation in organic chemistry, bioconjugation strategies, and complex biologics. At Regeneron, he founded and led a core research group, driving innovation in antibody-based therapeutics and overseeing the generation, characterization, and deployment of more than 1,000 proteins. His expertise spans protein engineering, antibody characterization, and developability assessments, with a strong focus on CMC strategies to ensure the manufacturability and stability of biologics. Passionate about advancing novel therapeutics, he also experiments with open-source models and code in his free time, exploring computational tools to accelerate drug discovery.

Nicole Beach
Nicole has over 20 years of experience as an Office Manager and Human Resources professional with experience in event planning, team building, and employee workplace management and deep experience in startups. With a Masters degree in Organizational Leadership specializing in HR Management, she is highly organized, extremely personable and professional.

Zachary Dobson, PhD
Biochemistry PhD in structural biology, specializing in protein engineering. With experience as a protein scientist in drug discovery, I am passionate about understanding and manipulating protein structures to innovate therapeutics. Dedicated to scientific excellence, I aim to contribute to the development of transformative solutions in healthcare. Outside of the lab you can find me in the mountains chasing Colorado cutthroats.

Mike Minson, PhD
Mike is an experienced research biochemist coming from ArcherDX and Sartorius with expertise in developing high throughput assays for cell screening using a variety of techniques including NGS, microscopy, and flow cytometry. During his postdoctoral and graduate work at the University of Colorado Boulder, he studied the immune response to bacterial infection using FRET biosensors in primary macrophages. Mike is focused on bringing the drug discovery and downstream analysis of candidates to scale.

Clara Ross, MS
Clara is a protein scientist coming from Watchmaker Genomics with 4+ years of experience in protein purification ranging from small scale prototyping to large scale manufacturing. She has additional experience in protein expression, characterization and DNA/RNA library preparation. Prior to her work in industry, Clara obtained her master’s degree from New Mexico State University where she studied Rho Family GTPases during oocyte meiosis using fluorescent biosensors and 3D live-cell microscopy.

Claire Armstrong, PhD
Claire has over 10 years of experience as a research scientist, specializing in high-throughput assay development, cellular signaling, and single-cell fluorescence microscopy. During her PhD and postdoctoral work at the University of Colorado, she studied the molecular mechanisms driving cell-cycle commitment using single-cell timelapse microscopy of fluorescent biosensors. Claire specializes in driving forward the selection and validation of therapeutic antibody scaffolds via cell-based assay development, single-cell screening, and cell picking microscopy.

Rachel Langston, PhD
Rachel is an experienced molecular biologist coming from Inscripta with expertise in DNA repair and genetics. She is skilled at developing protocols for large-scale mutagenesis. During her postdoctoral work at the IBPC she developed a novel CRISPR-based protocol to study DNA replication and telomere regulation. At BioLoomics, Rachel is focused on optimizing and scaling library production to more efficiently identify drug candidates.

Keiran McGee
Keiran is a graduate of the University of Colorado Boulder where he earned a Bachelor of Arts in Biochemistry. There, he gained lab-based research experience while working on the optimization of an RNA purification method for application in a novel biosensor production pipeline. He is excited to support the work of BioLoomics, while also being able to continue his involvement in research here on Colorado’s Front Range. Outside of the lab, Keiran doubles as a musician, playing bass in the CU Campus Orchestra and singing in the Rocky Mountain Chorale.

Kaitlyn Shafer
Kaitlyn holds a BS in Biochemistry from the University of Denver. She has experience implementing and creating quality control standards and protocols in the diagnostic industry. At BioLoomics, she supports our DNA and cell biology scientists with a wide range of daily tasks including solution preparation, experimental support at different stages, and inventory management. She's focused on developing industry skills in preparation for pursuing a graduate degree.

Ted Kee
Ted has over 12 years of biotech industry experience, specializing in Manufacturing Science and Technology (MSAT). He has held process development and engineering positions at several industry-leading pharmaceutical companies. Ted relocated to Colorado from California in 2019 to co-found BioLoomics and lead the effort to streamline, standardize, and scale up BioLoomics’ laboratory operations.

Jeremy Jacobsen, MS
Jeremy operates at the intersection of mechanical and electrical engineering and data analysis with an emphasis on biological data sets. Prior to joining BioLoomics, he was an analyst for the DARPA Rapid Threat Assessment project at the University of Colorado, Boulder. He specializes in large multidimensional datasets and has applied this expertise to proteomics, metabolomics, and microscopy data.
Our Board of Directors, Scientific Advisory Board and Technical Advisors

Nicholas Saccomano, PhD
Nick Saccomano joins the BioLoomics board of directors with over 35 years of research, development, and management experience across a multitude of therapeutic areas. Nick most recently served as Chief Science Officer and site head at Pfizer Boulder R & D, formally Array BioPharma Inc., where he grew and advanced a portfolio of small molecule oncology programs from inception to proof-of-concept. Over his varied career, Dr. Saccomano has guided the discovery and development of dozens of molecules resulting in several commercial introductions. Nick’s appointment will complement the strengths of the BioLoomics leadership and advisory groups, while contributing deep insights into platform development, strategic direction and portfolio/clinical applications.

Joel Dudley, PhD
Joel is a partner at Innovation Endeavors and an experienced leader, medical professional, researcher, and entrepreneur. Joel previously served as the Chief Scientific Officer at Tempus, a company focused on bringing the power of data and artificial intelligence to healthcare. Before joining Tempus, Joel was an Associate Professor of Genetics and Genomic Sciences and founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. He also served as Executive Vice President for Precision Health for the Mount Sinai Health System. Prior to joining Innovation Endeavors, Joel co-founded Onegevity Health (acquired by Thorne), a company developing health intelligence platforms for preventative health, and NuMedii, a company developing machine learning and A.I. approaches for drug discovery. Joel earned a BS in Microbiology from Arizona State University and an MS and Ph.D. in Biomedical Informatics from the Stanford University School of Medicine.

Natanel Barookhian
Starting with $10K in personal funds, Natanel Barookhian has guided, pruned, and grown TechU into one of the most selective and best-performing seed funds on the East Coast. Born into a single-parent home of modest means, Natanel’s worldview was shaped by early immigration to the United States. Armed with four languages and an MBA from MIT, he engages tenacious entrepreneurs from around the world in search of next-generation deep tech with lasting implications.

Peter Senter, PhD

Alan Wahl, PhD
Dr. Alan Wahl has 30+ years of successful research and drug development experience in oncology and immunological disease. He has key contributions to the discovery and clinical development of FDA approved carboplatin, TAXOL®, and ADCETRIS®. Alan has held scientific and executive leadership positions at Bristol Myers Squibb, Seagen (Seattle Genetics), Trubion, Biogen Idec, AbbVie, and Ambrx. He is a retained advisor to numerous biotech, pharma and venture capital firms. He holds over 40 issued patents and 60 publications in oncology drug discovery and targeted cancer therapies. Alan received his MS and PhD in Biochemistry and Biophysics at the University of Rochester and his post-doctoral training at Stanford University.

Steve Davidson, PhD
Steve Davidsen is a biotech executive with over 35 years of experience in drug discovery and development. He is Founder & President of Predawn Discovery Advisors LLC where he provides technical and strategic input to organizations engaged in therapeutic drug discovery. He served as Vice President, Oncology Discovery Research in AbbVie’s R&D organization from 2013 to 2023 where he was responsible for discovery efforts across all AbbVie Oncology programs and sites. He has directed research teams and partnerships leading to more than 40 first-in-human cancers clinical trials across a broad range of platforms (small molecules, biologics, drug conjugates, cell therapies) and biology (tumor intrinsic pathways, cell surface targets, immuno-oncology mechanisms) targeting both hematologic and solid tumor indications. He has more than 70 scientific publications and currently serves as an advisor for multiple organizations.

Tony Haight, PhD
Tony has 30 plus years of experience in pharmaceutical development. He has deep technical expertise in drug substance development including strategy, synthesis, supply chain, analytics, regulatory, and compliance for both early and late development of small molecules. Tony also has strong leadership and experience in drug-conjugate modalities, targeted degradation, biologics, collaborations, and organization of cross-disciplinary teams supporting pre-clinical to late-stage development.

Chris Bahl, PhD
Dr. Bahl is the President, CSO and Co-founder of AI Proteins in Boston, is an established leader in the protein design field, and was a 2019 TED Fellow. He holds a Ph.D. in Biochemistry from Geisel School of Medicine at Dartmouth, an MS in Biochemistry, and BS in Biochemistry, Molecular & Cellular Biology from the University of Maine. He pioneered the ability to computationally design miniproteins de novo as a postdoctoral fellow with Dr. David Baker at the University of Washington’s Institute for Protein Design in Seattle. Following his Post-Doc, he joined the Institute for Protein Innovation in Boston as one of the founding faculty members, with co-appointments at Boston Children’s Hospital and Harvard Medical School.

Jeanne Stachowiak, PhD
Professor Stachowiak is a Professor at UT Austin, Texas. Her interests are the biophysical mechanisms that underlie the function of lipid membranes in cells and creation of bio-inspired materials and systems that borrow these mechanisms. Themes of her work include: understanding how proteins and lipid domains modify the fluidity, reactivity, and 3D architecture of membranes, examining how confinement within a lipid vesicle influences biochemical reactions and spatial organization of biochemical components and using the organizational principles of the lipid membrane to build functional systems such as assays, drug carriers, and environmentally responsive materials.

Michael Stowell, PhD
Michael Stowell is CSO of AmideBio and an Associate Professor of Molecular Biology and Mechanical Engineering at the University of Colorado, Boulder. He has authored numerous publications in the fields of synthetic organic chemistry, structural biology, neurobiology, and biophysics. Michael has received multiple grants and awards including the Beckman Young Investigator Award, a National Institutes of Health EUREKA award and a Howard Hughes Medical Institute Collaborative Innovation Award. Michael received his Ph.D. in Chemistry and Biophysics from the California Institute of Technology and was a visiting Scientist at the MRC – Laboratory of Molecular Biology, Cambridge England and the Biophysics Department of Kyoto University, Japan.
Our Investors
